The argument builds on a striking real-world study that has recently energized the field. A retrospective, two-stage cohort analysis by Chen and colleagues examined early bone-marrow-guided venetoclax management in patients with newly diagnosed acute myeloid leukemia who were considered unsuitable for intensive chemotherapy. Among 371 evaluable patients, the investigators found that using early marrow assessments to guide treatment was associated with significantly reduced early venetoclax exposure and a marked drop in day-56 infection-related hospitalization, which fell from 37.4 percent to 24.0 percent, corresponding to an adjusted odds ratio of 0.46 with a p-value of 0.005. In other words, simply looking at the marrow earlier allowed clinicians to pull back on the drug before the most dangerous toxicities took hold.

The second stage of the Chen study sharpened the finding further. Among 237 patients who responded to initial therapy, shortening venetoclax to fourteen days or fewer per cycle reduced prolonged grade-4 neutropenia from 61.0 percent to 41.6 percent, an adjusted odds ratio of 0.41 with a p-value of 0.003. Infection-related hospitalization also fell, with an adjusted odds ratio of 0.43 and a p-value of 0.014. Critically, these toxicity reductions came without any significant change in measurable residual disease negativity, overall survival, or relapse-free survival. For a drug whose most feared side effect is profound, prolonged neutropenia that opens the door to life-threatening infections, the implication is provocative: some patients may be receiving more venetoclax than they need, and the excess exposure may be pure harm.

Yet the editorial is careful to frame these results as a beginning rather than an endpoint. Because the Chen study was retrospective, its findings are vulnerable to selection bias; clinicians may have shortened therapy preferentially in patients who already looked healthier, which could inflate the apparent safety benefit. The absence of randomization means the two compared groups may have differed in ways the statistical adjustments could not fully capture. Adnan also notes that the study showed no significant difference in overall survival or progression-free survival, which supports the idea that shortening was not harmful but does not prove that shortened venetoclax is truly equivalent in efficacy. Prospective, ideally randomized validation remains the essential next step before practice changes on a wide scale.

There is a deeper conceptual problem as well, and it sits at the heart of the proposed framework. Bone marrow morphology, the century-old practice of examining stained marrow smears under a microscope, is functional and widely available, but it is a blunt instrument. It can miss small populations of leukemic cells that persist below the threshold of visual detection, and its interpretation varies between observers. The editorial contends that early marrow morphology is useful but insufficient on its own, and that relying on a single marker to decide whether to curtail a backbone therapy in a disease as heterogeneous as acute myeloid leukemia is inherently risky.

This is where measurable residual disease enters the picture. A consensus document from the European LeukemiaNet MRD Working Party, authored by Heuser and colleagues, established MRD as a central biomarker in acute myeloid leukemia, serving prognostic, predictive, monitoring, and efficacy-response functions. A positive or negative MRD result indicates whether quantifiable disease is detected above specific thresholds, but those thresholds differ depending on the assay and the laboratory performing it. Flow cytometry, polymerase chain reaction-based assays for mutations such as NPM1, and other techniques each carry distinct sensitivities and limitations, which means an MRD result must always be interpreted in context rather than treated as an absolute verdict.

Recognizing these limitations, recent work by Bancos and colleagues has advocated a multimodal approach to residual disease assessment, tracing the evolution from cytogenetics and molecular biology to emerging technologies such as methylation pattern analysis and surface-enhanced Raman scattering. Each molecular marker, whether marrow morphology, conventional MRD, or molecular MRD via next-generation sequencing, may contribute to diagnosis and monitoring, but none is individually sufficient to guide every treatment decision. The editorial takes this logic one step further and applies it specifically to the question of venetoclax duration, proposing that the integration of multiple markers could provide a more precise and personalized basis for deciding when to stop or shorten therapy.

The framework also draws inspiration from the broader multi-omics movement in hematology. A review by Soleimani Samarkhazan highlighted how integrating complementary molecular and transcriptomic indicators can enable more accurate response-adapted approaches in acute myeloid leukemia, potentially allowing venetoclax duration to be customized according to both morphological and biological measures of disease response. Under such a model, a patient whose marrow clears rapidly, whose MRD assays turn negative early, whose leukemic clone shows molecular responses on sequencing, and whose blood counts recover promptly might safely de-escalate to shorter venetoclax cycles. Conversely, a patient with persistent molecular evidence of disease might continue full-dose therapy or be considered for escalation, even if the microscope looks reassuringly empty.

The stakes of getting this right are considerable. Acute myeloid leukemia is a progressively increasing form of leukemia with consistently high incidence and mortality, imposing a growing strain on health systems worldwide. Projections based on the Global Burden of Disease Study 2021 estimate that by 2040 the number of cases will rise significantly, with predicted figures reaching approximately 184,287.88 for incidence and 165,537.59 for mortality. The economic toll is equally sobering: a United States analysis by Hagiwara and colleagues of 9,455 newly diagnosed patients found that the average healthcare cost per patient was 386,077 dollars. Every day of unnecessary venetoclax exposure adds hospitalizations, growth factor use, transfusions, and infection management to that bill, while every day of insufficient exposure risks relapse, which is far more expensive and far more deadly.

What makes the editorial’s proposal compelling is that it reframes a question the field has been circling for years. Venetoclax-based regimens have delivered unprecedented response rates in unfit patients, but the drug’s hallmark toxicity, myelosuppression, has remained a stubborn constraint, and clinicians have lacked a principled way to know when enough is enough. By proposing a multi-marker panel that unites marrow morphology, MRD, molecular MRD via next-generation sequencing, and hematologic recovery, the editorial sketches a route toward treating venetoclax duration the way modern oncology treats nearly everything else: as a variable to be tuned by data rather than fixed by tradition. The author acknowledges the constraints of the underlying evidence, including the retrospective design of the pivotal real-world study and the possibility that no single marker can capture the full complexity of the disease. But the direction of travel is clear, and the call for prospective research into a multi-marker response-adapted framework gives the field a concrete hypothesis to test. If randomized studies confirm that response-guided shortening preserves survival while stripping away toxicity, the fixed ten-plus-month venetoclax paradigm could give way to something smarter, safer, and genuinely personal, and the editorial argues that the tools to build that future are already on the laboratory bench.

Subject of Research: Response-adapted venetoclax dosing guided by multi-marker disease assessment in acute myeloid leukemia

Article Title: Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia

Article References: Adnan, N. (2026). Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia. Annals of Hematology, 105(10), Article 414. https://doi.org/10.1007/s00277-026-07280-x

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07280-x

Keywords: acute myeloid leukemia, venetoclax, measurable residual disease, bone marrow morphology, next-generation sequencing, BCL-2 inhibitor, neutropenia, response-adapted therapy, multi-omics, hematology, treatment de-escalation, European LeukemiaNet

The stakes of the question are considerable. Multi-agent neoadjuvant therapy, meaning chemotherapy given before surgery, combined with the immune checkpoint inhibitor pembrolizumab, is the established standard for Stage II and III triple-negative breast cancer. That standard rests largely on the landmark KEYNOTE-522 trial, which showed that adding immunotherapy to neoadjuvant chemotherapy improved pathologic complete response rates, event-free survival, and overall survival. But the pivotal trials that cemented this approach either excluded patients with Stage I disease or failed to analyze them separately, leaving clinicians without direct evidence for the smallest tumors. Current National Comprehensive Cancer Network guidelines still recommend upfront surgery followed by adjuvant chemotherapy for node-negative tumors measuring one to two centimeters, reserving neoadjuvant strategies for higher-risk cases.

In practice, however, the lines are blurring. Neoadjuvant therapy offers real advantages: it tests a tumor’s chemosensitivity in the body, can shrink cancers enough to enable breast-conserving surgery, and provides a powerful prognostic signal. Patients who achieve a pathologic complete response, defined as no residual invasive disease at surgery, have excellent outcomes, while those with residual disease can be escalated to treatments such as adjuvant capecitabine, validated in the CREATE-X trial, or olaparib for patients with germline BRCA mutations, validated in the OlympiA trial. These residual-disease-directed strategies have given clinicians a practical reason to give therapy up front even when a tumor is small, since the response itself guides what happens next.

To map the contemporary landscape, the researchers assembled a cohort of 252 patients with T1-2N0M0 triple-negative breast cancer diagnosed between July 2021 and December 2024, then focused on a predefined small TNBC group of 215 patients: 154 with Stage I disease and 61 with node-negative Stage II tumors smaller than three centimeters. The cohort was demographically typical of triple-negative disease, with 82.5 percent grade 3 histology and 89.3 percent ductal histology. Overall, 70.6 percent of patients received neoadjuvant therapy, 98.8 percent underwent surgery, and 42.1 percent received adjuvant radiation. With a median follow-up of 2.6 years, recurrence occurred in 18 patients and death in 11, reflecting the generally favorable prognosis of small, node-negative tumors.

The most striking finding was the asymmetry between biology and treatment. Demographically, the Stage I and small Stage II groups were nearly indistinguishable, with similar ages, menopausal status, comorbidities, and BRCA mutation prevalence. Histopathologically they overlapped as well, although grade 3 histology was more common in the Stage II, under-three-centimeter group. Yet treatment diverged sharply. Neoadjuvant therapy was given to 85.2 percent of small Stage II patients versus 61.0 percent of Stage I patients. The KEYNOTE-522 regimen, combining chemotherapy with pembrolizumab, dominated both groups but was used far more often in Stage II disease, at 75.0 percent versus 45.7 percent. Adjuvant pembrolizumab followed the same pattern, given to 56.8 percent of small Stage II patients compared with 24.7 percent of Stage I patients.

Despite these markedly different treatment intensities, outcomes converged. Recurrence rates were 6.5 percent in the small Stage II group versus 3.3 percent in Stage I, and mortality rates were 1.9 percent versus 6.6 percent, neither difference statistically significant. Among the 146 patients treated with neoadjuvant therapy, the pathologic complete response rate was 51.3 percent overall, and it was essentially identical across the stage boundary: 51.1 percent for Stage I versus 51.9 percent for small Stage II tumors. No individual regimen separated itself from the pack. KEYNOTE-522 achieved a pCR rate of 52.4 percent in the combined small TNBC cohort, statistically indistinguishable from anthracycline-taxane regimens at 50.0 percent, carboplatin-taxane plus pembrolizumab at 45.8 percent, and other neoadjuvant approaches at 55.0 percent.

Survival analyses told a similar story of convergence. Event-free survival did not differ significantly between patients who received neoadjuvant therapy and those who did not within the small TNBC cohort, nor between Stage I and small Stage II patients treated with neoadjuvant therapy. Even within the KEYNOTE-522-treated subgroup, event-free survival did not significantly differ by stage. The authors caution that these survival findings are exploratory, limited by short follow-up, few events, and the selection biases inherent in any retrospective design. Treatment assignment was not randomized, and confounding by indication, in which sicker-appearing patients receive more intensive therapy, cannot be excluded. Subgroups were also small, precluding robust multivariable modeling.

Still, the pattern is clinically meaningful. The authors note that immune checkpoint inhibitors can produce durable endocrinopathies such as adrenal insufficiency or insulin-dependent diabetes, toxicities that weigh heavily in patients whose tumors already carry a favorable prognosis. Intensifying therapy for a two-centimeter node-negative tumor while withholding the same regimen from a 2.1-centimeter tumor, purely because it crosses an arbitrary size threshold, may not reflect underlying biology. The data suggest that node-negative tumors just below and above the two-centimeter T1c-T2a boundary may behave more alike than staging conventions assume, and that a size-based framework for small triple-negative breast cancer could better contextualize treatment decisions than the current stage-based one.

The study team is already moving toward prospective answers. Their center is conducting DETENTE-1, a phase 2 randomized pilot study in Stage I triple-negative breast cancer comparing three neoadjuvant strategies: carboplatin plus paclitaxel, carboplatin plus paclitaxel plus pembrolizumab, and pembrolizumab monotherapy. Such de-escalation trials could identify which small tumors truly need intensified chemoimmunotherapy and which can be spared its costs. The authors envision integrated risk-stratification models incorporating tumor size, genomic data, immune biomarkers, toxicity risk, and cost considerations to individualize neoadjuvant selection. For now, the message for patients and clinicians is nuanced: small node-negative triple-negative breast cancers respond to modern therapy at high rates and with low recurrence, but the evidence base for choosing among regimens remains thin, and the conventional stage boundary may be a poorer guide to biology than anyone assumed.

Subject of Research: Neoadjuvant therapy patterns and outcomes in small node-negative triple-negative breast cancer

Article Title: Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study

Article References: Lee, B., Santos, B., McArthur, H., LeVee, A., Kordic, A., Zhang, S., & J. Gruber, J. (2026). Contemporary therapy for small node-negative triple-negative breast cancer: a retrospective cohort study. Breast Cancer Research and Treatment, 219(3), Article 15. https://doi.org/10.1007/s10549-026-08074-5

Image Credits: AI Generated

DOI: 10.1007/s10549-026-08074-5

Keywords: triple-negative breast cancer, neoadjuvant therapy, pembrolizumab, KEYNOTE-522, pathologic complete response, Stage I breast cancer, immunotherapy, cancer staging, treatment de-escalation, retrospective cohort study, event-free survival, breast-conserving surgery

Oropharyngeal squamous cell carcinoma, which arises in the tonsils and base of the tongue, has become increasingly common in developed countries, driven largely by HPV infection. Tumours linked to the virus respond unusually well to treatment, and patients with HPV-positive disease enjoy substantially better survival than those whose cancers are tobacco-related. That favourable biology has fuelled a worldwide effort to de-escalate therapy: if standard treatment cures more than 90 percent of patients, clinicians argue, the intensity of that treatment can perhaps be reduced without compromising outcomes. Radiation, even in modern intensity-modulated form, carries a heavy burden of long-term toxicity, including dry mouth, difficulty swallowing, neck stiffness, hypothyroidism, and, in some patients, the need for long-term feeding tubes.

Previous de-escalation attempts have taken two broad routes. One approach reduces the dose of radiation delivered after biopsy-definitive diagnosis, as tested in trials such as E1308 and OPTIMA, which used induction chemotherapy to select patients for reduced-dose chemoradiation. Another strategy replaces radiation with transoral surgery, exemplified by the E3311 trial of transoral robotic surgery with risk-based adjuvant therapy and the ORATOR randomised comparison of surgery versus radiotherapy. The Japanese trial takes a distinctive third path: it uses chemotherapy first to shrink the tumour, then performs less invasive transoral surgery, and withholds all postoperative radiation when pathology shows the disease has been eradicated.

In the trial, 32 eligible patients with HPV-associated resectable oropharyngeal cancer received three cycles of NAC-TPF before undergoing surgery. Thirty patients successfully underwent transoral surgery after the chemotherapy, and an R0 resection, meaning complete removal of the tumour with clear microscopic margins, was confirmed in 31 patients. The primary endpoint was the centrally reviewed pathological complete response rate, in which pathologists examine the surgical specimen and find no residual viable cancer. The pCR rate reached 65.6 percent, and a virological complete response, in which no high-risk HPV RNA could be detected in tumour specimens from either the primary site or the lymph nodes, was achieved in 64.5 percent of patients.

Although the trial formally missed its prespecified primary endpoint, the investigators concluded that the response rate was clinically meaningful and, more importantly, that the treatment sequence allowed 91 percent of patients to avoid postoperative radiotherapy or postoperative chemoradiotherapy entirely. For those patients, the entire course of cancer care consisted of chemotherapy followed by surgery, sparing them the swallowing dysfunction, xerostomia, and fibrosis that radiation to the throat typically causes. The trial was registered as jRCT1041220029 and was supported by the Japan Agency for Medical Research and Development, with participation from more than a dozen Japanese institutions including Shizuoka Cancer Center, National Cancer Center Hospital, and several university hospitals.

The study went beyond pathology to track molecular and patient-reported outcomes. Researchers measured levels of high-risk HPV RNA in tumour specimens and circulating tumour HPV DNA in blood plasma, an emerging biomarker that reflects fragments of DNA shed by tumour cells into the bloodstream. After neoadjuvant chemotherapy, 23 patients showed undetectable levels of circulating tumour HPV DNA, suggesting that the molecular footprint of the cancer had been eliminated in most participants. Liquid biopsy monitoring of this kind is increasingly viewed as a promising tool for identifying which patients can safely forgo intensive adjuvant therapy and for detecting recurrence earlier than imaging alone.

Quality of life was assessed prospectively using validated instruments, including the 30-item European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. All measured quality-of-life scores returned to baseline values or improved within one year of treatment. This finding stands in sharp contrast to the trajectory often seen after chemoradiotherapy for head and neck cancer, where studies have documented persistent declines in swallowing, dry mouth, and social functioning years after treatment completion. For a disease that disproportionately affects middle-aged adults, the ability to return to baseline function within a year represents a substantial practical benefit.

The biological rationale for the approach rests on the chemosensitivity of HPV-positive tumours. Viral oncogene-driven cancers undergo apoptosis more readily when exposed to DNA-damaging agents, and prior pathological studies of p16-positive oropharyngeal carcinoma have shown deep tumour regression after neoadjuvant chemotherapy. By administering chemotherapy before any local therapy, clinicians can also gauge response directly: the surgical specimen provides definitive pathological evidence of how completely the tumour was eradicated. Patients whose specimens show residual disease can still receive postoperative radiation or chemoradiotherapy as salvage, which is precisely why the trial design preserved standard adjuvant treatment for the minority who needed it.

The trial’s limitations are those inherent to a single-arm Phase II study of modest size. Without a randomised control group, the durability of disease control and survival cannot be established, and longer follow-up will be required to confirm that avoiding radiation does not compromise cure rates in the 91 percent of patients who skipped it. The primary endpoint threshold was not met, meaning the results cannot by themselves change practice guidelines. Nevertheless, the investigators argue that the combination of a 65.6 percent pathological complete response rate, near-universal R0 resection, molecular clearance of circulating tumour HPV DNA in most patients, and full quality-of-life recovery constitutes a compelling signal that deserves testing in larger, ideally randomised, Phase III studies.

The findings arrive amid a rapidly evolving landscape of de-escalation research. Recent trials have explored neoadjuvant immunotherapy combined with chemotherapy before transoral surgery, including studies of nivolumab and sintilimab, and long-term follow-up of E3311 has continued to support risk-based adjuvant treatment decisions after robotic surgery. The Japanese trial adds an important data point: chemotherapy-first sequencing can convert a substantial fraction of HPV-associated oropharyngeal cancers into surgically curable disease without any radiation exposure. If ongoing and future studies confirm these results, the standard of care for HPV-positive throat cancer could shift decisively away from radiotherapy-based regimens toward response-adapted strategies in which the intensity of treatment is tailored to how completely each patient’s tumour responds to initial systemic therapy.

Subject of Research: Neoadjuvant triplet chemotherapy as a radiotherapy-sparing strategy for HPV-associated oropharyngeal squamous cell carcinoma

Article Title: Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial

Article References: Yokota, T., Tsuzuki, T., Onitsuka, T., Iizuka, A., Ouchi, Y., Mori, T., Tsukahara, K., Hanyu, K., Mukaigawa, T., Nakashima, T., Uryu, H., Omura, G., Nakamura, H., Uemura, H., Nishikawa, D., Kano, S., Akiyama, Y., Onoe, T., Oyamada, S., & Yamaguchi, T. (2026). Neoadjuvant triplet chemotherapy enables radiotherapy avoidance in human papillomavirus–associated oropharyngeal cancer: a multicentre Phase II trial. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03610-y

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03610-y

Keywords: HPV-associated oropharyngeal cancer, neoadjuvant chemotherapy, NAC-TPF, transoral surgery, radiotherapy de-escalation, pathological complete response, circulating tumor HPV DNA, Phase II trial, quality of life, head and neck cancer, British Journal of Cancer, treatment de-escalation